2847775-88-4
2847775-88-4
Chemical Structure
L-Octanoylcarnitine-d9
- CAS No.: 2847775-88-4
- Formula:C15H20D9NO4
- Molecular Weight:296.45
InChIKey: CXTATJFJDMJMIY-UKACUGSRSA-N
SMILES: CCCCCCCC(O[C@H](CC([O-])=O)C[N+](C([2H])([2H])[2H])(C([2H])([2H])[2H])C([2H])([2H])[2H])=O
Biological Activity: L-Octanoylcarnitine-d9 is deuterium labeled L-Octanoylcarnitine. L-Octanoylcarnitine is a plasma metabolite and a physiologically active form of octanoylcarnitine. L-Octanoylcarnitine can be used for the research of breast cancer[1][2][3].[1][2][3][4].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
L-Octanoylcarnitine-d9 | 99.9% | L-Octanoylcarnitine-d9 is deuterium labeled L-Octanoylcarnitine. L-Octanoylcarnitine is a plasma metabolite and a physiologically active form of octanoylcarnitine. L-Octanoylcarnitine can be used for the research of breast cancer.. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
L-Octanoylcarnitine (Standard) | ≥98% | L-Octanoylcarnitine (Standard) is the analytical standard of L-Octanoylcarnitine. This product is intended for research and analytical applications. L-Octanoylcarnitine is a plasma metabolite and a physiologically active form of octanoylcarnitine. L-Octanoylcarnitine can be used for the research of breast cancer. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
L-Octanoylcarnitine-d3 | L-Octanoylcarnitine-d3 is the deuterium-labeled L-Octanoylcarnitine (HY-113161). L-Octanoylcarnitine-d3 is a plasma metabolite and a physiologically active form of octanoylcarnitine. L-Octanoylcarnitine-d3 can be used for the research of breast cancer. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
L-Octanoylcarnitine | 98.0% | L-Octanoylcarnitine is a plasma metabolite and a physiologically active form of octanoylcarnitine. L-Octanoylcarnitine can be used for the research of breast cancer. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216. [Content Brief]
- [2]. Hanna Kosnik, et al. CHRONIC HIGH FAT DIET IMPAIRS DETRUSOR MITOCHONDRIAL FATTY ACID OXIDATION IN MALE BUT NOT FEMALE MICE. Journal of UrologyBladder & Urethra: Anatomy, Physiology & Pharmacology I (MP11)1 Apr 2019.
- [3]. Kim M, et al. Association between arterial stiffness and serum L-octanoylcarnitine and lactosylceramide in overweight middle-aged subjects: 3-year follow-up study. PLoS One. 2015 Mar 17;10(3):e0119519. [Content Brief]
- [4]. Schönfeld P, Reiser G. Inhibition of β-oxidation is not a valid therapeutic tool for reducing oxidative stress in conditions of neurodegeneration. J Cereb Blood Flow Metab. 2017 Mar;37(3):848-854. [Content Brief]
